- The ReXista(TM) product demonstrated sustained release
pharmacokinetic activity, with blood plasma concentrations at
clinically significant levels over a 24 hour period.
- The bioavailability of a single dose of the ReXista(TM) product, as
measured by Cmax and AUC, was comparable to that of two doses of
Oxycontin(R) dosed at 12 hour intervals. Both Cmax and AUC were in
the 80% - 125% range as compared to Oxycontin(R), demonstrating
effective bioequivalence with the branded product.
The Company intends to release detailed results of this pilot clinical trial after further study and analysis. Dr. Isa Odidi, CEO and Chief Design Officer for IntelliPharmaCeutics, stated "We are very encouraged by these early results. The ReXista(TM) delivery technology was developed entirely in-house, and is unique in the industry. We are excited that our new ReXista(TM) dosage form, which resists dose-dumping in the presence of alcohol, and which has great potential to resist oral, nasal and intravenous abuse, has already demonstrated controlled release to a once-a-day standard and effective bioequivalence with the twice daily branded product. With these results in hand, we will certainly move rapidly to advance the development into a full clinical trial program. We will also now apply the Rexista(TM) technology to other narcotic analgesic agents in our development pipeline."
IntelliPharmaCeutics is a drug delivery innovator and developer,
specializing in the controlled and targeted once-a-day delivery of oral,
solid dose pharmaceutical products. It operates from a 25,000 sq ft
research laboratory and manufacturing scale-up facility located adjacent to
Toronto International Airport. The Company utilizes proprietary, patented
and proven drug
|SOURCE IntelliPharmaCeutics Corp.|
Copyright©2008 PR Newswire.
All rights reserved